Integrating Clinical, Protein Expression, and Genetic Markers to Predict Lymphedema in Breast Cancer
NCT ID: NCT07252843
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
133 participants
OBSERVATIONAL
2022-10-11
2025-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Can clinicopathological factors predict the development of lymphedema?
* Do protein expression profiles and genetic mutations increase susceptibility to lymphedema?
Participants will:
* Undergo clinical evaluation and indocyanine green (ICG) lymphography to diagnose lymphedema.
* Provide lymphatic tissue and blood samples during ALND surgery for immunohistochemical protein analysis and gene mutation assessment.
* Be followed over time to monitor the onset and progression of lymphedema.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection
NCT01969253
The Effectiveness of Lymphatic Bypass Supermicrosurgery
NCT05682885
Nomogram to Predict Breast Cancer Related Lymphedema
NCT04665882
Lymphedema Surveillance Study
NCT02743858
Predictors of Lymphedema Following Breast Cancer Surgery
NCT00202046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histopathologically confirmed breast cancer
* Undergoing axillary lymph node dissection (ALND)
* Able to undergo indocyanine green (ICG) lymphography examination
Exclusion Criteria
* History of iodine allergy, asthma, impaired renal function, pregnancy, or breastfeeding
* Incomplete clinical or laboratory data required for analysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fakultas Kedokteran Universitas Indonesia
OTHER
Dharmais National Cancer Center Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rizky Ifandriani Putri
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rizky Ifandriani Putri, MD
Role: PRINCIPAL_INVESTIGATOR
Anatomical Pathology Department, Dharmais Cancer Hospital - National Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dharmais Cancer Hospital
Jakarta, DKI Jakarta, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
308/KEPK/IX/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.